PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘positive’) with our company headquarters located in Austin, TX.  We also have a manufacturing facility in San Antonio, TX and a satellite office in San Diego, CA.

The lead drug product candidate in our pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals.  This diverse and experienced team is using our proprietary and versatile nanotechnology platform to reformulate and improve conventional, workhorse chemotherapeutics to provide meaningful benefits to patients and healthcare providers.  The platform also serves as the foundation and affords us the opportunity in the future to develop additional drugs for oncology and other therapeutic areas.


We believe in the critical importance of discovering, developing, and delivering complex and innovative treatments for patients battling cancer and other life-threatening diseases.


We envision medicines that will drastically enhance clinical and economic outcomes for patients and providers and forever change the future of human health worldwide.


Our company values guide our beliefs, behaviors, and interactions.  

Our goal is to live out these values everyday, everywhere, and with everyone.


Reliability, responsibility, and taking ownership of our work.


Ability to quickly respond and adapt to internal and external changes without losing our momentum.


Welcome transparency and direct feedback from colleagues, partners, providers, and patients alike.


Possess ongoing curiosity and courage to boldly experiment and discover.


Consistently remain ethical and commit to always doing the right thing, no matter what.


Keep our passion for the patient forever at the forefront of all we do.



Promise to deliver exceptional results and continually strive to enhance our standards.


Focus on achievement, taking smart risks, and delivering exceptional results.



Treat everyone we come in contact with dignity and kindness.


Cultivate a culture that encourages collaboration and welcomes different perspectives.



Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.


Desiree Smith

Corporate Controller and Principal Financial and Accounting Officer

Desiree Smith is the Corporate Controller and principal financial and accounting officer at PLUS THERAPEUTICS, Inc.  Ms. Smith joined us from Outlook Amusements, Inc., where she last served as Controller from March 2018 to June 2019. Prior to joining Outlook Amusements, Inc., Ms. Smith served as Controller at XPEL Technologies, Inc. from April 2016 to July 2017. Ms. Smith also served as Controller at Globalscape, Inc. from May 2009 to July 2014 and served as Interim Chief Financial Officer and principal accounting officer at Globalscape, Inc. In addition, Ms. Smith served as Assistant Controller at Harte Hanks, Inc. from July 2014 to May 2015. Ms. Smith has also held positions at Kimco Realty, USAA Real Estate Company and Sirius Computer Solutions from April 2000 to May 2009. Ms. Smith is a Certified Public Accountant with over 35 years’ experience in accounting and finance.


Cheri Rice

Vice President - Product Development

Cheri Rice is the Vice President of Product Development at PLUS THERAPEUTICS, Inc.  She previously served in the same role at Cytori Therapeutics Inc.  Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Cytori. Ms. Rice has her bachelor’s degree in Mechanical Engineering from San Diego State University.


Russ Havranek

Vice President - Marketing, Portfolio Management, Investor Relations

Russ Havranek is the Vice President of Marketing, Portfolio Management, and Investor Relations at PLUS THERAPEUTICS, Inc.  He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics Inc.  Mr. Havranek has over 20 years of marketing, general management, and product development experience with major life science companies including Johnson & Johnson, Guidant Corporation (now Abbott), Genentech Inc. (now Roche), and Volcano Corporation (now Philips).  Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.



Richard Hawkins


Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2018. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Gregg Lapointe


Gregg Lapointe has served on our Board since March 2017. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company. From April 2008 to March 2012, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.pA. He served as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from November 2003 to March 2008. Mr. Lapointe also serves on the boards of SciClone Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company (since March 2009), Soligenix, Inc., a publicly-held biopharmaceutical company (since March 2009), Immunocellular Therapeutics, Ltd., a publicly held pharmaceutical company (since September 2015) and S1Biopharma, Inc. a privately held biopharmaceutical company. Mr. Lapointe previously served as a director of Raptor Pharmaceuticals Corp. from December 2014 until its acquisition by Horizon Pharma plc in October 2016. Mr. Lapointe is a Certified Public Accountant in the United States. He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and an M.B.A. from Duke University. Mr. Lapointe’s qualifications to sit on our Board include his substantial experience in finance, management and specialty drug commercialization, including operational experience as the CEO of a pharmaceutical development and sales organization.

Ronald Martell


Ronald A. Martell joined our Board in December 2016. Mr. Martell has more than 25 years’ experience building and managing unique businesses in the biotech industry, and most recently served as Executive Chairman of KaloBios and as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma.


Powered by People, Equipment, Facilities, Suppliers

We have completed facility validations at our recently acquired nanoparticle manufacturing facility located in San Antonio, Texas, USA.  The facility and processes are designed to comply with cGMP per FDA and EMA regulations to manufacture drug candidates for research, development, clinical, and commercial use. Upon approval of our drug product candidates, our manufacturing capabilities will include validated manufacturing processes for drug product as well as a quality assurance product release process with the ability to ultimately scale-up the process to meet increasing market demands. We believe our strategic investments in the analytical and manufacturing capabilities, including personnel from drug discovery through drug development, will allow us to advance our product candidates more rapidly.

Expertise gained in manufacturing DocePLUS™ and DoxoPLUS™ may be applied to other formulations in the future, allowing us to further leverage our capabilities. Our San Antonio facility enables us to produce drug product in a cost-effective manner while retaining control over the process and timing. As needed, the use of a qualified Contract Manufacturing Organization may be utilized to perform various manufacturing processes as we deem appropriate to meet our operational objectives.

Our current principal suppliers for our business are Bryllan, which provides sterile filling activities for our drug candidates, LGM Pharma and ScinoPharm Taiwan, which supply our active pharmaceutical ingredients, or APIs, doxorubicin and docetaxel, respectively, as well as Lipoid, LLC and Dishman Netherlands, which supply us with other raw materials used in the manufacture of our DocePLUS™ and DoxoPLUS™ drug candidates.


Why Join Us?

At PLUS THERAPEUTICS our employees are dedicated to developing and delivering innovative nanomedicines to health care providers and their patients. Because we believe that each employee contributes directly to our growth and success, we strive to encourage both their professional and personal development.

We foster a work place culture in which our employees are respected and valued so that we may recruit and retain the best people for our innovative, fast-paced, and exciting business.

We are an equal opportunity employer dedicated to diversity and fairness in the work place and invites you to submit your resume.


There are no job openings at this time.


PLUS THERAPEUTICS strives to provide its team with a comprehensive, competitive, and flexible selection of benefits to build health, wealth, and quality of life.

Vacation (Paid Time Off - PTO)

Enjoy time off on us. A balanced work life increases productivity. PLUS THERAPEUTICS offers paid time off, to be used for vacation and and sick time, and eleven (11) paid holidays.


Healthy employees mean a healthy work force. We understand that a comprehensive health and wellness program is key to maintaining a healthy and positive staff. PLUS THERAPEUTICS offers health coverage including medical, dental, and vision insurance plan options. We also offer flexible spending accounts to help reserve pre-tax dollars for health needs.

Life Protection

PLUS THERAPEUTICS’ insurance plans provide peace of mind. Our benefits program includes basic and voluntary life insurance options, as well as short-term and long-term disability insurance plans to replace a portion of your income in the event of injury, illness, or death.

Retirement Planning

Reaching your retirement and savings goals is simplified through PLUS THERAPEUTICS’ 401(k) Retirement Savings Plan. The plan is a convenient way for our people to save for retirement and meet future financial goals.

Employee Assistance

Life can become overwhelming at times, but help is just a call or click away with our employee assistance program (E.A.P.). PLUS THERAPEUTICS’ E.A.P. is designed to provide counseling 24/7 for employees and their family members regarding a variety of issues in or outside the home, from financial advice to conflict resolution at no additional cost.